NEW YORK (GenomeWeb News) — Agilent Technologies will manufacture the small-interfering RNA component of an RNAi therapeutic being developed by Intradigm, the firms said last week.
 
Agilent will supply the siRNA material for use in Intradigm’s preclinical oncology candidate, ICS-283. According to the firms, ICS-283 is the only RNAi therapeutic in development against a clinically validated oncology target, in this case vascular endothelial growth factor.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.